Company

As the founder and Chief Executive Officer (CEO) of TCUBEit, I have dedicated more than 25 years to research and development in T-cell immunology, exploring adoptive T-cell therapies and the molecular mechanisms of immune recognition.

I previously served as CTO of M5 Bioscience Group, Senior Researcher at Medytox Inc., and Visiting Research Fellow in T-cell Biology at the Korea Research Institute of Bioscience and Biotechnology (KRIBB). Throughout my career, I have led numerous drug development projects in the fields of autoimmunity and immuno-oncology.

I earned my Ph.D. in Immunology and Biophysics from KAIST and conducted research on antibody engineering and structural modeling at the Institute for Protein Research in Osaka, Japan. Later, I served as an Instructor at the Dana-Farber Cancer Institute and Harvard Medical School, where I studied the molecular structure and signaling mechanisms of T-cell receptors (TCR) and CD3 subunits.

Building on this extensive research experience and industry insight, I will continue to lead TCUBEit as a pioneering immunotherapy company, committed to developing patient-centered innovative treatments.